ETON Stock Forecast & Price Target

Eton Pharmaceuticals is positioned favorably because its 3Q26 revenue of $57.9M beat consensus by a wide margin, surged 158% year over year, and lifted annualized sales beyond its $200M run-rate goal five quarters early. The core growth drivers are commercial execution and portfolio breadth: HEMANGEOL’s relaunch has already produced record patient counts across multiple brands, while LIBERVANT could add a new neurology franchise in April 2027, subject to FDA approval and exclusivity constraints. Profitability and liquidity also support the bull case, as adjusted EBITDA reached $28.5M, or 49% of revenue, gross margin expanded to 80%, and cash from operations was $35M with $55.6M in cash and just $22M of debt outstanding.

Eton Pharmaceuticals is facing a fundamental clinical and development risk in ET-700, because the November 5, 2026 pilot study showed improved tolerability but materially weaker efficacy, with only a 12% reduction in hepatic copper uptake versus 46% for GALZIN. The results suggest the extended-release zinc acetate is releasing too slowly to block copper absorption in the small intestine, and the need for faster-release formulations pushes the pivotal study start to late 2027 at the earliest. That delay, combined with uncertainty over whether efficacy can be improved without sacrificing the safety advantage, weakens the near-term investment case despite the company’s eight commercial products and five late-stage candidates.